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Abstract1
Vaccines that autonomously transfer among individuals have been proposed as a strategy to control2 infectious diseases within inaccessible wildlife populations. However, rates of vaccine spread and3 epidemiological efficacy in real world systems remain elusive. Here, we investigated whether topical4 vaccines that transfer among individuals through social contacts can control vampire bat rabies, a5 medically and economically important zoonosis in Latin America. Field experiments in 3 Peruvian6 bat colonies which used fluorescent biomarkers as a proxy for the bat-to-bat transfer and ingestion7 of an oral vaccine revealed that vaccine transfer would increase population-level immunity up to 2.68 times beyond the same effort using conventional, non-spreadable vaccines. Mathematical models9 demonstrated that observed levels of vaccine transfer would reduce the probability, size, and duration10 of rabies outbreaks, even at low, but realistically achievable levels of vaccine application. Models11 further predicted that existing vaccines provide substantial advantages over culling bats, the policy12 currently implemented in North, Central, and South America. Linking field studies with biomarkers13 to mathematical models can inform how spreadable vaccines may combat pathogens of health and14 conservation concern prior to costly investments in vaccine design and testing.15
Introduction16
Infectious diseases of wildlife cause threats to human and animal health globally [1]. Controlling these17 pathogens within their natural animal hosts can offer substantial health, economic, and conservation18 benefits. For example, baited vaccines targeting wildlife reservoirs eliminated fox rabies from western19 Europe [2] and currently confine raccoon rabies to the eastern United States [3]. However, for many20 important wildlife diseases, delivery systems to vaccinate a sufficient proportion of host populations to21 control pathogens are unavailable, and direct (i.e., individual-based) vaccination is logistically prohibitive.22 Interventions that spread from treated to untreated individuals are increasingly used to control arthropod-23 borne diseases [4, 5, 6] and have been proposed as a solution to mass vaccinate wildlife since each24 unit of vaccine deployed would immunise multiple individuals [7, 8]. However, as seen with poliovirus25 eradication efforts, vaccines that sustain transmission may revert to virulent phenotypes [9], and in wildlife,26 vaccine shedding may have unanticipated ecological or evolutionary impacts on competing pathogens or27 host species [10]. Vaccines with deliberately constrained capacity to transmit are therefore currently28 the preferred candidates for real world applications. Encouragingly, theoretical models suggest that29 such weakly-transmissible vaccines consistently outperform individual-based vaccination, increasing the30
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potential for disease eradication [11]. Despite this theoretical promise, spreadable vaccines have only31 rarely been tested in natural systems (i.e., rabbit hemorrhagic disease and myxomavirus in rabbits [12]).32 This gap between theory and practice reflects a number of limiting factors: vaccines may be unavailable;33 epidemiological knowledge of the target pathogen or the dynamics of vaccine spread may be insufficient34 to guide deployment or predict benefits; and losses incurred under existing management strategies may35 be considered insufficient to warrant the real or perceived risks of novel interventions.36 Vampire bat rabies (VBR), a universally lethal viral zoonosis found throughout Latin America, rep-37 resents a tractable system to explore the implementation of spreadable vaccines to protect human and38 animal health. Where common vampire bats (Desmodus rotundus) routinely feed on human blood, VBR39 is estimated to cause up to 960 deaths/100,000 people [13]. Losses from livestock mortality exceed $5040 million annually and disproportionately affect impoverished, rural communities [14, 15]. Existing manage-41 ment strategies have been unable to mitigate the burden of VBR. Vaccines for humans and livestock are42 protective, but high costs and inaccessibility to remote areas limit uptake [16]. Rabies control programs43 also cull vampire bats using anticoagulant poisons (’vampiricide’) which are applied in topical gels that44 spread among bats through social contacts and are ingested during grooming (here termed ’orotopical45 transfer’) [17]. While culling reduces bat bites on humans and livestock, effects on rabies transmission46 remain controversial [18, 19]. Moreover, heightened bat dispersal following culls is predicted to exacerbate47 VBR transmission by increasing the mixing of bat colonies, analogous to the increased transmission of48 bovine tuberculosis induced through effects of culling on badger home range size [20, 21]. Oral rabies49 vaccines that spread by the same orotopical mechanism as vampiricide offer an alternative approach.50 These recombinant virally-vectored vaccines can indirectly immunise untreated bats in captivity, but have51 never been tested in wild populations [22, 23, 24, 25]. Several unresolved questions must be answered52 prior to deploying vaccines for large scale bat rabies control: (1) how efficiently would vaccines transfer53 among wild bats?, (2) are certain demographic groups of bats especially difficult to vaccinate or especially54 effective disseminators of vaccines?, (3) would the resulting degree of immunisation significantly reduce55 rabies transmission?, and (4) would vaccines reduce human and livestock rabies risk more effectively than56 the current policy of culling? We address these questions by coupling field studies that used fluorescent57 biomarkers to quantify contact networks and orotopical transfer among wild vampire bats with mathemat-58 ical models that simulated how vaccines and vampiricide, which spread by identical mechanisms, would59 impact the size, duration, and probability of rabies outbreaks.60
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Results61
Biomarker transfer and ingestion shows potential for high vaccine coverage in wild vampire62 bats63
We estimated the potential for a spreadable vaccine to transfer among bats using Rhodamine b (RB), a64 biomarker that when ingested leads to long-lasting fluorescence in hair follicles in diverse mammalian65 species [26, 27, 28]. After applying a gel-formulation of RB topically to bats in three colonies in Peru66 (colony sizes: 207-257 individuals, sex ratios: 43.1-50.6% male), orotopical transfer and ingestion was67 monitored by fluorescent microscopic analysis of hair samples collected in subsequent capture sessions,68 with fluorescence indicating RB consumption (Supplementary Table 1). At two sites (LMA5 & LMA6), an69 estimated 84 and 92% of bats ingested RB, either following topical application or transfer from treated bats70 (Fig. 1). The third colony (LMA12) relocated to an undocumented roost soon after RB treatment, which71 diminished captures during the monitoring period relative to the estimated colony size (Supplementary72 Table 1); consequently, the overall estimated coverage dropped to 28.8% (Fig. 1). Nevertheless, the73 percentage of sampled LMA12 bats at the end of the monitoring period that were RB positive (48.3%,74 aggregating days 24 and 25), was not statistically different from the percentages at the final capture75 dates in the other two colonies (58.3 and 70.0%; Chi-squared test, χ2 = 3.2, df = 2, p = 0.21). We76 further characterized patterns of RB uptake among demographic groups of bats. The sex ratios of transfer77 positive bats became slightly more male biased (3-11% increases, depending on the colony) relative to78 the sex ratios of bats that were treated with RB, suggesting elevated transfer to males; however these79 increases were not statistically significant (χ2 tests, all p > 0.05; Supplementary Figure 1). We observed80 RB transfer to untreated bats in all three age classes. Across all colonies, 86.1% of sampled adults (N =81 374), 75.8% of sampled juveniles (N = 33), and 94% of sampled subadults (N = 34) became RB positive82 through transfer during the 1 month monitoring period. Consequently, these results implied that vaccines83 deployed over only two days of captures (17-50% of total colony size) would yield high levels of population84 immunity across age classes due to orotopical transfer.85
Contact heterogeneities among demographic groups of vampire bats86
We next examined whether contact heterogeneities might make certain demographic groups of bats espe-87 cially effective or ineffective spreaders of vaccines using ultraviolet (UV) powder marking, wherein different88
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age/sex groups of bats were treated with different colors of UV powder, and transfer to untreated bats was89 monitored over two subsequent capture nights [29, 30]. Across 3 replicate UV treatments per colony, we90 documented 78 instances of UV powder transfer, leading to estimated contact rates ranging from 0.23–1.2591 per treated bat (Fig. 2). Male bats had significantly higher contact rates than females (Wilcoxon rank92 sum test, W = 91, p = 0.025; mean = 1.14 versus 0.67) and had similar rates of male-to-male and93 male-to-female contacts (Wilcoxon rank sum test, W = 42, p = 0.93). In contrast, females preferentially94 contacted other females (Fig. 2a). Transfer to juveniles could not be reliably quantified because these95 bats were mostly too young to forage independently and our capture method during the monitoring period96 required bats to fly out of roosts. Nevertheless, a single juvenile bat captured had UV transfer from a97 female. In contrast, transfer from juveniles to adults should have been detectable if it occurred due to the98 greater ease of capturing adults. However, none of the 27 marked juveniles transferred UV powder to99 adults. Together with our data illustrating high rates of juvenile exposure to RB, these findings suggest100 that vaccine deployments should target adults rather than juveniles. Targeting adults would further be101 logistically advantageous since it would minimize social disruption of colonies that results from entering102 roosts to capture juveniles.103
Epidemiological models show spreadable vaccines outperform culling for rabies control104
We adapted a deterministic compartmental model of VBR persistence [20] to incorporate an orotopically105 spread vaccine and used least-squares (Fig. 3b) to estimate expected per capita vaccine transfer rates from106 the time series of RB transfers observed in our field studies, assuming that RB transfer equated to lifelong107 protection. This analysis revealed that each treated bat transferred RB to 1￿45−2￿11 untreated individuals,108 up to a 2.6-fold increase in population level coverage relative to the coverage that would be expected using109 conventional, non-spreading vaccines (Fi.g 4b, Supplementary Figure 2 and Supplementary Table 2). We110 simulated the ability of spreadable vaccines to control rabies across the range of R0 values (0.6 to 2)111 suggested in the rabies literature [20, 34, 35]. Applying vaccines to approximately 20% of bats vaccinated112 40% of the population and reduced rabies outbreak size by 45 to 75%, depending on the assumed R0 of113 rabies (Fig. 4a,b,c). However, applying vaccines to a higher proportion of bats had diminishing returns for114 both the proportion of the colony that was ultimately protected and for rabies control. If vaccines were115 applied to >30% of bats, additional reductions in rabies outbreak sizes were less than 5%, meaning a 5%116 increase in initial application led to less than a 5% reduction in outbreak sizes (Fig. 4d). The greatest117
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benefit (reduction in outbreak size relative to effort) occurred at vaccination levels below 15%.118 We next compared the relative efficacy of vaccination and culling across three epidemiological sce-119 narios [21]. representing different management strategies: (1) a ’preventative’ approach, where vaccine/-120 vampiricide was applied to prevent VBR invasion into historically rabies–free bat populations [33, 36];121 (2) a ’proactive’ approach, which represented an intervention in a VBR endemic area, but in a colony122 that was not currently infected; and (3) a ’reactive’ approach where intervention followed 60 days after a123 single VBR-infected bat was introduced to the colony (Supplementary Figure 4). Although we simulated124 outcomes across the full possible range of application effort (i.e., 0-100% of bats treated), we focused on125 lower application levels since capturing large proportions of bats across large geographic areas would126 be impractical for rabies control campaigns. Indeed, mark-recapture studies across multiple vampire bat127 colonies in Peru suggested that on average, <10% of colonies were captured in a single night [19]. At128 realistic levels of application, vaccination consistently reduced the probability of viral invasion, outbreak129 size, and outbreak duration more effectively than culling, regardless of whether control was preventative,130 proactive, or reactive (Fig. 5). Culling was only favored when at least 25% of the colony was treated,131 and only in reactive scenarios. However, the advantage of culling on outbreak size was relatively small132 - a maximum of a 20% greater reduction - relative to the larger advantages observed when vaccination133 was favored (up to 45% greater reduction), and differences in outbreak duration were negligible until134 much larger proportions of bats were culled (Fig. 5). In preventative and proactive scenarios, culling135 required capturing and treating much larger proportions of vampire bat populations (e.g., >60%) to match136 the reduction in outbreak size and duration achieved by vaccination (Fig. 5). In fact, the only discernible137 difference at higher application levels was a greater reduction in the duration of outbreaks by culling;138 however, this was due to near complete extinction of bat colonies. Even if this degree of bat culling were139 achievable and ethically acceptable, it may not be a favorable long-term strategy since populations that140 recovered from culls would be entirely susceptible to rabies, potentially causing larger future outbreaks141 [37].142 Our per capita transfer rates likely represented lower bounds of vaccine and vampiricide spread since143 the relatively high percentage of bats initially treated with RB left few others available to be exposed144 via transfer in two of our colonies and relocation of the third colony reduced capture rates during the145 monitoring period. Indeed, some studies have suggested higher transfer rates of vampiricide [17, 39].146 We therefore conducted a sensitivity analysis where both vaccines and vampiricide spread up to 10-fold147
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more efficiently than our RB estimates, values that exceeded the largest transfer rates suggested from148 vampiricide releases. Additionally, we considered transfer rates that were up to 75% less efficient than our149 RB estimates. This analysis demonstrated that low-level vaccination remained favored under preventative150 and proactive approaches even if both the vaccine and vampiricide spread up to 3-fold greater than151 observed in our field studies (Supplementary Figures 7-9). If both interventions spread less effectively152 than RB, vaccination was either superior or equivalent to culling except when large proportions of bat153 colonies were reactively culled (Supplementary Figure 6). Under realistic levels of application (application154 ≤ 25%), even if vampiricide spread 3-fold better than a vaccine, it was unable to outperform vaccination155 under preventative or proactive approaches when R0 was less than 2. Under reactive scenarios, culling156 was favored if vampiricide spread 2-3-fold better than a vaccine or if VBR R0 was 2 (Supplementary157 Figure 9). Given that existing oral rabies vaccines use replication-competent viral vectors with potential158 for lower effective doses than chemical poisons [24, 25], heightened vampiricide transfer is less likely than159 the converse where vaccines spread better [8, 40]. The high R0 scenarios where culling was favored are160 also unlikely, as the estimated VBR R0 is considerably lower than 2 [20]. Our results therefore support161 previous suggestions that culling may require near-elimination of bats to locally benefit rabies prevention162 [18] and reveal spreadable vaccines as efficient tools to reduce the size, duration, and probability of rabies163 outbreaks in Latin America.164
Discussion165
This study demonstrates proof-of-principle that at operationally-achievable levels of deployment and166 empirically-quantified rates of bat-to-bat spread, orotopical vaccines should reduce rabies transmission167 more effectively than culling, the current policy employed across Latin America. Since VBR persistence168 requires inter-colony spread for viral dispersal, even modest reductions in outbreak size are likely to169 have epidemiologically important impacts at the larger geographic scales over which disease control170 campaigns are implemented. In particular, by reducing the number of infected bats and the probability171 of viral invasion, vaccination of a limited number of colonies would disproportionately benefit regional172 rabies elimination by favoring stochastic viral extinctions. Because male dispersal spreads rabies between173 colonies, vaccination might further benefit from targeting male bats [33]. Although higher rates of social174 grooming among females was expected to undermine this strategy [39, 41], we found that males have equal175
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or greater inter- and intra-sex contact rates, a possible consequence of attempted mating with females or176 fighting among males. Importantly, because self-grooming is common [42], any vaccine transferred through177 these interactions would ultimately be ingested.178 Designing large-scale campaigns to deploy spreadable rabies vaccines requires additional research in179 several areas. First, to optimize the number of vaccine doses to apply to each bat, captive and field studies180 should quantify individual heterogeneity in transfer rates using actual vaccines in addition to biomarkers.181 Second, the costs of vaccination must be estimated in economic terms in addition to the epidemiological182 assessment provided here. Unfortunately, vaccines are currently produced only for research and costs of183 large-scale production are unavailable. Third, vaccination of vampire bats without population reduction184 will be unacceptable to some stakeholders since uncontrolled bat depredation sustains exposures to non-185 rabies pathogens [43] and anemia from bites may reduce livestock productivity independently of rabies186 [44]. Given that culling shifts bat populations towards younger, more rabies susceptible individuals, which187 could enhance rabies transmission [19], future research should develop tools for reproductive suppression188 as an alternative to culling [45]. Finally, metapopulation maintenance of rabies provides opportunities189 for more efficient, epidemiologically-informed vaccination [46]. For example, vaccines might be deployed190 with prior knowledge of rabies presence from livestock surveillance systems (e.g., ring vaccination) or191 preventatively in areas where the locations and timing of outbreaks are predictable [36]. Spatially-192 explicit rabies transmission models will be an important next step to design these interventions, but will193 require a more quantitative understanding of bat dispersal than is currently available. Excitingly, once194 strategies are developed, the operational capacity for their implementation is already available in most195 Latin American countries through decades of experience with culling campaigns.196 These results provide evidence that spreadable vaccines may contribute to pathogen management197 within wild bats. VBR provided an ideal case study because the epidemiological mechanisms underlying198 viral maintenance are understood and candidate vaccines are available [20, 25, 36, 47]. While the exact199 parameter estimates and models developed here should not be applied directly to other bat pathogens,200 the framework linking biomarkers to mathematical models can guide future research. For several bat201 pathogens of public health or conservation concern such as White Nose Syndrome, Hendra virus, and202 Marburg virus, epidemiological models have been proposed [48, 49, 50] and vaccines for bats either exist203 or have precedents encouraging their development [51, 52, 53]. In these cases, our approach could be204 implemented over relatively short timescales to evaluate the prospects for vaccines to aid management and205
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the immunological and epidemiological characteristics that would be required for success before investing206 resources in vaccine development. For other bat pathogens with greater uncertainty in reservoir hosts207 and transmission biology, such as Ebolaviruses [54], implementation will require greater fundamental208 knowledge of viral transmission cycles. We encourage further development of virally-vectored vaccines209 for bats and highlight the need to quantify their spread and efficacy in the wild.210
Methods211
Field studies of biomarker transfer and ingestion212
Field studies were carried out between January and July 2017 in three vampire bat roosts in the Barranca213 (LMA5, -10.6415, -77.8160), Huaura (LMA6, -11.0555, -77.4594), and Lima (LMA12, -12.1833, -76.8500)214 provinces of the Department of Lima, Peru (Supplementary Table 1). Two roosts (LMA5 and LMA6) had215 been monitored since 2007, while the third (LMA12) was examined here for the first time [19]. All roosts216 were man-made tunnels that formed part of crop irrigation systems. Diurnal captures were carried out217 to mark bats and estimate sex ratios and colony sizes. Diurnal captures involved teams entering caves218 and catching bats with hand nets (BioQuip, Tropics Net). In addition, 2.5-meter mist nets (Ecotone) were219 placed at each end of tunnels to catch bats that attempted to escape. Diurnal capture effort was set to 1220 hour across sampling dates and localities. Colony sizes were estimated using the Schnabel method [55].221 Nocturnal captures were carried out in the same roosts to monitor biomarker spread. Nets placed at each222 roost exit were checked every 30 minutes for 4 hours per night at varying hours depending on the lunar223 cycle. Following removal from mist nets, bats were placed in individual cloth bags until processing. All224 captured bats were given an individually numbered, 4 digit incoloy wing band (3.5mm Porzana Inc.) to225 identify recaptures. Age was classified as juvenile, subadult, or adult based on the degree of fusion of226 the phylangeal epiphyses [56]. In total, we recorded 1777 captures of 709 individually-marked bats, with227 the average bat captured 2.39 times (range=1-9).228 Studies of vaccine transfer and ingestion used RB powder (50mg) mixed with glycerine jelly (44.5ml,229 Carolina Biological Supply Company) and water (55.5ml) to form a gel. On days 1 and 2, RB was230 administered orally to confirm fluorescence in RB-treated bats (ca. 0.05ml via needle-free syringe) and231 applied topically (ca. 0.45ml, rubbed into the dorsal fur) to all captured bats. Uptake in un-treated bats232 was monitored using hair plucked from bats captured over 4-5 subsequent sessions per colony, carried233
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out up to 31 days after initial application (Supplementary Table 1). Hair samples were examined with a234 Nikon SMZ1270 microscope at 15x using a fluorescence filter with excitation wavelength 540 nm, emission235 wavelength 625 nm. Each sample was examined by two individuals to minimize misclassification, except at236 LMA12 on days 8 & 10, where only one individual examined the hair. The presence of fluorescence in hair237 was interpreted to indicate transfer and consumption of RB, but was not considered a quantitative measure238 of the volume of RB consumption. Because bats had identification tags, we were able to distinguish those239 that were positive due to transfer from RB treated bats (”transfer positives”) from those that had RB applied240 by experimenters (”application positives”). Hair samples were collected under the Peruvian collection241 permit, 028-2017-SERFOR/DGGSPFFS and exported to the United States under export permit, 3235-242 SERFOR. This research was performed under approval of University of Glasgow School of Veterinary243 Medicine Animal Ethics Committee (Project 25A/18).244
Contact heterogeneities among demographic groups of vampire bats245
Powder marking was replicated 3 times per colony (total of 9 marking sessions) and bats were monitored246 for two nights following each marking session (Supplementary Table 1). During each session, red, green,247 blue, or orange UV powder (DayGlo Corp.) was rubbed into the fur of the bat across the entire body248 using a toothbrush, with colors dependent on age and sex. UV colors were rotated between groups at249 different capture dates to control for potential differences in detection probability. UV powder markings250 were recorded by examining each captured bat for 30s using handheld UV lights (Glowtech Ltd.) prior251 to removal from mist nets. After removing UV marked bats from the recaptures, directional contact rates252 for each sex (e.g. female-to-male contacts per marked female) were calculated using equation 1:253
Contact Rate = N￿￿￿XUMX ∗NUMXMX ￿ (1)
where N￿￿￿X is the number of bats of a certain sex testing positive for the UV color in question, UMX254 is the number of unmarked bats of that sex captured at this time point, NUMX is the number of unmarked255 bats of that sex in the entire colony, and MX is the number of initially marked bats from that sex. Example256 calculations are provided in the Supplementary Information (Eqs. 2 & 3).257 Sex biases in UV transfer were tested by comparing all estimated rates from males to all estimated258 rates from females, treating each site, month, and recipient sex combination as independent observations259
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(N = 36). We used a non-parametric Wilcoxon rank sum test since rates were not normally distributed,260 even after log transformation (Shapiro-Wilk test, p = 0.01).261
Parameter estimation and mathematical modeling262
Per capita rates of orotopical transfer and ingestion, defined as the estimated number of bat-to-bat263 transfers per treated individual, were estimated using the data from our RB field study. Specifically,264 we incorporated a susceptible (S), application positive (A), and transfer positive (T) deterministic com-265 partmental model (Fig. 3b) using least-squares methods in the statistical software R. A 2-day transfer266 period was integrated with the number of RB application and transfer positives across time to estimate267 the expected transfer rate of orotopical vaccines or poisons (β). A 6-day RB transfer period was also268 considered to examine variation in β across time (Supplementary Table 2, Supplementary Information).269 We assumed that successful transfer led to death in culling models and lifelong protection against VBR in270 vaccination models (ca. 3.5 years of protection given the lifespan of D. rotundus, Supplementary Table 3).271 Importantly, waning of vaccine-induced immunity would not alter the results shown here which focused272 on single outbreaks.273 Mathematical models of rabies control used a stochastic model that simulated both rabies transmission274 and vaccine transfer. A susceptible (S), application positive (A), transfer positive (T), exposed to rabies (E),275 immune (I), and rabid (R) model, with a daily time-step, was simulated for 5000 iterations using a Gillespie276 algorithm (Fig. 3a, Supplementary Information). Following previous models of vampire bat rabies [20] and277 consistent with the absence of strong relationships between colony size and rabies seroprevalence [19],278 we utilized a frequency-dependent rabies transmission function. We used 237 bats as the colony size279 (the mean size from our three field sites). The base model without vaccination or culling followed the280 mathematical structure and parameter values used by Blackwood et al. [20], with the simplifications of a281 single infectious class and modeling a single introduction of rabies rather than sustained introductions282 via immigration. This model generated similar outbreak dynamics to the Blackwood et al. [20] model,283 characterized by short lived outbreaks (less than 1 year) followed by viral extinction, persistence of the284 bat population, and seroprevalence levels consistent with field observations, particularly at values of R0 >285 0.6 (Supplementary Figure 3). Since we modelled our vaccine spread on a recombinant Raccoonpox virus-286 vectored vaccine that appears unlikely to spread via an infectious process (i.e., from indirectly vaccinated287 bats) [47], vaccines were modelled to spread only from those bats to which the vaccine was applied,288
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creating a single generation of transmission. Based on the very low prevalence of rabies in free-flying289 bats (>1%) and infrequent dispersal in vampire bats [57, 58], we simulated introduction of a single rabid290 bat to the population. Given that sex differences in RB transfer were non-significant and age-biased291 transfer was difficult to quantify due to small sample sizes in non-adult classes, we opted against more292 complex age and sex structured models of rabies and vaccine/vampiricide spread.293 Models comparing the efficacy of vampiricide to vaccination used the same model structure with the294 exception that bats in the exposed class died from ingesting vampiricide, while those that consumed295 the vaccine were not protected (see Eqs. 8 & 9 in the Supplementary Information). This was because296 post-exposure vaccination has not been evaluated in bats. We generally assumed equal transfer rates297 of vaccines and vampiricide based on their identical mechanism of transfer; however, we relaxed this298 assumption in the Supplementary Information (Supplementary Figures 6-9). We also assumed that both299 spread over relatively short time periods since vampire bats are exceptional groomers and would quickly300 ingest vaccine or vampiricide [42]. Importantly, our focal vaccine remains viable over these timescales301 [59]. After two years (730 days) the cumulative number of newly infected bats was considered to be the302 outbreak size. Outbreak duration was defined as the total number of days with at least one bat in the303 exposed class. For preventative and proactive approaches, we quantified the probability of an outbreak304 as the proportion of simulations where at least 1 new bat became infected after a single rabid bat was305 introduced.306
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Figure 1: Transfer and ingestion of an orotopically spread gel biomarker in three vampire bat colonies. In eachpanel, LMA5 (a), LMA6 (b), and LMA12 (c), x-axes are the days since RB application with the number of transferpositive bats over total captures in subtext. The y-axis is the number of bats in each colony within three categoriesRB negative (white), application positive (black), or transfer positive (gray). Asterisks (*) on and after day 10from LMA12 indicate captures from the second LMA12 roost. Data are the mean of microscopy readings from twoobservers, except where noted otherwise.
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Figure 1: Transfer and ingestion of an orotopically spread gel biomarker in three vampire bat colonies. In eachpanel, LMA5 (a), LMA6 (b), and LMA12 (c), x-axes are the days since RB application with the number of transferpositive bats over total captures in subtext (Pos/caps). The y-axis is the number of bats in each colony within threecategories RB negative (white), application positive (black), or transfer positive (gray). Asterisks (*) on and afterday 10 from LMA12 indicate captures from the relocated roost. Data are the mean of microscopy readings from twoobservers, except where noted otherwise. Transfer positive bats from day 2 had RB applied and are included in theblack bar to visualize the total force of application, but were included as transfers in statistical analyses.
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Figure 4: Simulating rabies outbreaks with vaccination. a, Mean rabies outbreak sizes after a single rabid batis introduced to the colony one week following immunisation. Colors represent varying degrees of rabies R0, with95% confidence intervals calculated from 5000 simulations. Dashed lines indicate the percent of bats that RB wasapplied to in each of our study sites. Supplementary Figure 5 shows results calculated only from simulations whereoutbreaks occurred. b, Total percent of bats protected based on initial vaccination, circle size indicates outbreaksize under the three rabies R0 values. Solid line represents the 1:1 line, points over the line represent the addedbenefit of spread. c, Reduction in rabies outbreak size (% fewer cases) under varying initial vaccination levels andrabies R0 values. d, Percent of additional rabies cases prevented by increasing initial vaccination 5% (rate of changein rabies reduction from the panel c).
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Figure 4: Simulating rabies outbreaks with vaccination. a, Mean rabies outbreak sizes after a single rabid batis introduced to the colony one week following release of a spreadable vaccine. Colors represent varying degreesof rabies R0, with 95% confidence intervals calculated from 5000 simulations. Dashed lines indicate the percentof bats that RB was applied to in our study sites. Supplementary Figure 5 shows results calculated only fromsimulations where outbreaks occurred. b, Percent of bats ultimately protected by initial vaccine release. Circle sizeindicates outbreak size under the three rabies R0 values. Solid line represents the 1:1 line; points over the linerepresent the added benefit of vaccine transfer. c, Reduction in rabies outbreak size (% fewer cases) under varyinginitial vaccination levels and rabies R0 values. d, Percent of additional rabies cases prevented by increasing theinitial vaccine release effort by 5% (i.e., the rate of change in rabies reduction from the panel c).
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Figure 5: Effects of preventative (a-c), proactive (d-f ), and reactive (g-h) strategies of culling and vaccination onrabies outbreaks. The first column shows the difference in the reduction of rabies cases; y-values above 0 favorvaccination and below 0 favor culling. The second column is the chance of a rabies outbreak under various conditionsover 5000 simulations. For each R0 value (blue, green, red) at various initial application levels (x-axis), for eachculling (triangles) and vaccination (circles), the chance of a rabies outbreak is shown. Shaded regions representthe difference between vaccination and culling, with culling favored in grey regions and vaccination favored inblue, green, or red regions. The probability of outbreaks was not modelled for reactive control since, by definition,outbreaks had already occurred. The third column shows the length of a rabies outbreak under various R0 conditionsfor both vaccination and culling. The horizontal line in panel H is at day 60, the day reactive control measureswere implemented.
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1 Field studies of biomarker transfer and ingestion13
1.1 Sampling schedule for field studies in Peru14
Supplementary Table 1 describes the marking and sampling schedule for the 3 field sites we examined.15
16
17 LMA5 LMA6 LMA12Date Experiment Treated/Caught Date Experiment Treated/Caught Date Experiment Treated/Caught
4/20/2017 RB mark M 25/25, F 30/30, J 2/2 4/22/2017 RB mark M 23/23, F 39/40, J 6/6 1/31/2017 RB mark M 7/8, F 11/11, J 3/34/21/2017 RB mark M 19/26, F 31/37, J 0/1 4/23/2017 RB mark M 15/23, F 25/37, J 0/2 2/1/2017 RB mark M 8/14, F 17/23, J 4/54/29/2017 RB recapture M 0/47, F 0/36, J 0/6 5/1/2017 RB recapture M 0/21, F 0/39, J 0/4 2/6/2017 RB recapture & UV mark M 10/13, F 24/26, J 5/54/30/2017 RB recapture M 0/29,F 0/38, J 0/3 5/2/2017 RB recapture M 0/27, F 0/49, J 0/7 2/8/2017 UV recapture & RB recapture M 0/13, F 0/8, J 0/05/6/2017 RB recapture M 0/24, F 0/36, J 0/8 5/8/2017 RB recapture M 0/33, F 0/46, J 0/7 ∗2/24/2017 RB recapture M 0/11, F 0/3, J 0/35/7/2017 RB recapture M 0/23, F 0/17, J 0/2 5/9/2017 RB recapture M 0/23, F 0/38, J 0/7 ∗2/25/2017 RB recapture M 0/10, F 0/3, J 0/05/18/2017 RB recapture & UV mark M 23/24, F 27/27, J 3/3 5/22/2017 RB recapture & UV mark M 15/15, F 16/16, J 4/4 ∗7/2/2017 UV mark M 41/41, F 65/65, J 8/85/19/2017 UV recapture M 0/10, F 0/14, J 0/0 5/23/2017 UV recapture M 0/17, F 0/15, J 0/0 ∗7/3/2017 UV recapture M 0/8, F 0/9, J 0/05/20/2017 UV recapture M 0/7, F 0/11, J 0/0 5/24/2017 UV recapture M 0/5, F 0/14, J 0/0 ∗7/4/2017 UV recapture M 0/9, F 0/11, J 0/06/21/2017 UV mark M 27/27, F 28/28, J 7/7 6/29/2017 UV mark M 17/17, F 26/26, J 0/0 ∗7/29/2017 UV mark M 45/45, F 67/67, J 11/116/22/2017 UV recapture M 0/7, F 0/10, J 0/0 6/30/2017 UV recapture M 0/5, F 0/6, J 0/0 ∗7/30/2017 UV recapture M 0/11, F 0/25, J 0/07/23/2017 UV recapture M 0/6, F 0/2, J 0/0 7/1/2017 UV recapture M 0/4, F 0/8, J 0/07/25/2017 UV mark M 26/26, F 28/28, J 10/10 7/22/2017 UV mark M 20/20, F 18/18, J 0/07/26/2017 UV recapture M 0/7, F 0/2, J 0/0 7/23/2017 UV recapture M 0/4, F 0/6, J 0/07/27/2017 UV recapture M 0/4, F 0/4, J 0/0 7/24/2017 UV recapture M 0/3, F 0/2, J 0/0
18
Supplementary Table 1: Field experiment schedule in three wild vampire bat colonies in Peru. RB/UV markindicates dates when rhodamine b or UV powder was applied to captured bats. RB/UV recapture indicates datesfor RB sample collection and UV powder monitoring, respectively. The treated/caught column lists, by sex orjuvenile, the number of bats treated and caught at each sampling date. Bats listed as a juvenile were not includedin the male or female groupings. ∗ Designates sampling from the relocated LMA12 roost.19
2 Contact heterogeneities among demographic groups of vampire bats20
2.1 Estimation of sex-specific contact rates from UV powder transfer21
A worked example of Eq. 1 from the main text, using data from the May sampling at LMA6 for male22 transfers can be seen in Eq. 2 & 3 below. During the marking period, green UV powder was applied to23 15 adult male bats. At the 24-48h recapture period, 4 of 24 captured females were green UV positive24 and 3 of 17 captured males were green UV positive. The estimated population size of LMA6 was 20725 bats (119 females and 88 males). Since 15 males were initially marked with green UV, only 73 males26 had the potential to test newly positive, while all 119 females were available for green UV transfer. As27
3
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Supplementary Figure 1: Sex ratio of application positives (left column) and transfer positives results from twoobservers (center and right columns). While the proportion of transfer positive males increased marginally from thelevels at application, differences were not statistically significant (chi-squared test: p > 0.05 for all comparisons).
a reminder, we have reproduced Eq. 1 from the main text;28
Contact Rate = N￿￿￿XUMX ∗NUMXMX ￿ (1)
Male-to-female (Eq. 2) and male-to-male (Eq. 3) contact rates are therefore estimated as follows:29
Male-to-Male = 317 ∗ (73)15 ￿ (2)
Male-to-Female = 424 ∗ (119)15 ￿ (3)
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3 Parameter estimation and mathematical modeling30
3.1 Least-squares estimation of RB transfer31
A deterministic least-squares compartmental model (Fig. 3b) was used to estimate the biomarker (RB)32 transfer rate (Supplementary Figure 2). Specifically, we estimated this parameter using application and33 transfer positive time series data (i.e. the number of successful transfers over time) and the population34 estimates from each sampling location (Fig. 1). Transfer rates were estimated using both a 2-day and a35 6-day transfer period (Supplementary Figure 2 & Supplementary Table 2). To be conservative, we used36 the lower mean transfer rate value (1.83) for the full outbreak model examined in the main text. The37 transfer parameter was estimated using least-squares in the deSolve package in R. Additional details are38 provided in Supplementary Software 1.39
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Supplementary Figure 2: Estimating the biomarker transfer parameter from field data using a least-squares fit.This parameter was estimated for both 2-day (a) and 6-day (b) transfer periods, with minimal differences in estimatedtransfer rate values (Supplementary Table 2). Curves were produced from plotting the model with the best-fit βvalues for each site.
40
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Supplementary Figure 2: Estimating the biomarker transfer t r from field d ta using a least-squares fit.This parameter was estimated for both 2-day (a) and 6-day (b) tr f eriods, with m nimal differences in estimatedtransfer rate values (Supplementary Table 2). Curves were produced from plotting the model with the best-fit βvalues for each site.
40
Transfer Time LMA5 LMA6 LMA12 Mean
2 days 2.11 (2.10-2.12) 1.92 (1.92-1.94) 1.45 (1.41-1.48) 1.836 days 2.24 (2.21-2.23) 1.99 (1.97-2.00) 1.74 (1.70-1.79) 2.00
41
Supplementary Table 2: β estimates from two different transfer periods (2 or 6 days) with 95% confidence intervals.42
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3.2 Mechanistic model of rabies control with spreadable vaccines43
We built a stochastic susceptible (S), application positive (A), transfer positive (T), immune (I), exposed44 to rabies (E), and rabid (R) model (Fig. 3a) to understand how the application and transfer of a vaccine45 or poison would alter rabies outbreaks in bat colonies. The structure of vaccination and culling models46 were identical except that vaccines were not assumed to protect bats that were incubating previous rabies47 exposures, but vampiricide was assumed to kill incubating bats (compare Eq. 8 versus Eq. 9 below).48 For both vaccination and culling models, all bats began in the S class, where they could be applied49 the orotopical gel at rate α , be bitten by a rabid bat at rate θ, or be exposed to the gel at rate β . Bats50 in all classes had a natural death rate, ω, equivalent to a lifespan of 3.5 years. Bats entered the S class51 through births (η, Eq. 5) or through the decay of natural immunity (φ), as described in Turmelle et al. [1]52 (see Supplementary Table 3 for details).53
￿S￿￿ = Nη + Iφ − S(α + ω)− β
￿SAN
￿− θ￿SRN
￿ (4)
Birth rate, η, was set equal the natural death rate of 3.5 years, with a seasonal birth pulse early in the54 year, estimated in Blackwood et al. [2] and adding 3￿475 ∗ 10−4 to keep all values positive.55
η = (8￿4563 ∗ 10−4) cos(2π(t− 32￿6747)/365) + 0￿0003475 (5)
Bats entered the A class through the manual application of a topical gel (α) and were able to transfer56 the gel for 2 days before moving into the T class at rate ψ , where they were no longer able to transfer57 the vaccine.58 ￿A￿￿ = Sα − A(ψ + ω) (6)
Naturally immunized bats (I) arrived from the E class at rate λ. It was possible for an immune bat to59 re-enter the susceptible class through loss of natural immunity, φ. Bats in the I class were able to move60 to the T class through contact with the A class through gel transfer (β).61
￿I￿￿ = Eλ− β
￿ IAN
￿− I(φ + ω) (7)
All exposed bats entered from the S class after being exposed to rabies (θ). They left by developing62
6
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immunity (λ) or became rabid (δ). These values were estimated by Blackwood et al., where 10% of exposed63 bats developed rabies and 90% acquired transient immunity [2]. In the vaccination models, vaccines were64 assumed not to protect bats that were exposed to rabies (E) prior to vaccination since the vaccine is a65 prophylactic meant to prevent infection, rather than a post-exposure prophylaxis. Instead those bats had66 the same probability of naturally surviving the rabies exposure and if they survived, they transferred to67 the T class (Eq. 8). In contrast, for the culling models exposed bats that ingested poison during the68 incubation period were killed regardless of whether or not they may have developed rabies (Eq. 9).69
￿EV￿￿￿￿ = θ
￿SRN
￿− β ￿EAN
￿ λ− E (λ+ δ + ω) (8)
￿EC￿￿￿￿￿ = θ
￿SRN
￿− β ￿EAN
￿− E (λ+ δ + ω) (9)
Rabid bats entered through those in the E class that developed rabies (δ) and left by dying from rabies70 (τ).71
￿R￿￿ = Eδ − R (τ + ω) (10)
Bats entered the T class by decaying in from the applied class after two days (ψ) and from the S, I, or E72 classes through transfer following contact with a bat in the A class73
￿T￿￿ = Aψ + β
￿(S + I) AN
￿+ β ￿EAN
￿ λ− Tω (11)
Parameters for the mathematical models were obtained from previous field or modelling studies and74 controlled infections in captive bats (Supplementary Table 3). Annotated R scripts for conducting math-75 ematical modeling are provided in Supplementary Software 2. All models were implemented using the76 tau-leap (Gillespie algorithm) method in R.77
78
79
7
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Description Parameter Value Citation/notes
Seasonal birth rate η See Eq. 5 [3, 4]Applied bats α varies (0-100%) NABat lifespan 1/ω 3.5 years [5, 6]Duration of orotopical gel transfer 1/ψ 2 days 48 hour transfer periodImmunity length 1/φ 4.5 months [2]Vaccine & vampiricide transfer β 0.9322064 Fitted from field data (Supplementary Figure 2)Duration of time in rabid class 1/τ 11 days [7]Rabies transmission rate θ R0 = 0.6-2 [2, 8]Mean time in E class - 21 days [7]Develop immunity λ 0.90 [1, 2], see textDevelop rabies δ 0.10 [1, 2], see text
80
Supplementary Table 3: Parameters used in the rabies transmission and control models.81
3.3 Model validation82
We validated our model against previously published work examining bat population dynamics [9], sero-83 prevalence [2], and prevalence [10] associated with rabies in bats (Supplementary Figure 3). Specifically,84 we expected our model to produce short-lived outbreaks that had minimal impacts on total bat popula-85 tion size, had moderate seroprevalence (generally, 0-40%), and were associated with a low prevalence of86 active infection ( 1%). We simulated the model for three rabies (R0) values without vaccination or culling87 to demonstrate that the model generates these dynamics in the absence of interventions. Supplementary88 Figure 3 shows bat population dynamics, seroprevalence, and infection prevalence across 1000 simulated89 introductions of rabies along with the seroprevalence data from Blackwood et al. [2] (Supplementary Table90 1, all observations of colonies with N>1) in order to compare to the range of seroprevalence values from91 our simulations to field observations. This model generated the expected prevalence during outbreaks and92 spanned the expected variation in seroprevalence. Moreover, the model generated qualitatively similar93 dynamics to the current understanding of rabies transmission dynamics described above.94
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spanned the expected variation in seroprevalence. Moreover, the model generated qualitatively similar93 dynamics to the current understanding of rabies transmission dynamics described above.94
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Supplementary Figure 3: 1000 simulations of the base model (Fig. 1a) with no vaccination or culling. Top rowis the colony population (start N=237), middle row is seroprevalance, and bottom row is prevalence. Columnsrepresent simulations assuming different levels of (R0). Colored lines indicate individual simulations with themedian simulation value in a solid black line and mean simulation value as a dashed line. To the far right of theseroprevalence column are the field seroprevalence data from Blackwood et al. [2]
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3.4 Description of timelines used to model alternative intervention strategies95
We explored three control strategies for rabies outbreaks: preventative, proactive, and reactive (Supple-96 mentary Figure 4) [11]. Preventative involved applying an orotopical gel (either a vaccine or vampiricide)97 to bats one week before a rabid bat was introduced to the colony; proactive was the same except that98 10.5% of the population (N=25 bats) were considered to be protected by previous natural exposure [2].99
9
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Reactive control introduced a rabid bat on day 1 and simulated orotopical application on day 60. This100 delay was intended to account for time that would be required for one round of transmission within the bat101 colony (21 day incubation period), infections in livestock to occur (21 day incubation period), be detected102 and be diagnosed (11 days), as well as time for logistical planning and implementation of campaigns (7103 days). Reported incubation periods in livestock range from 12-40 days in experimental infections, de-104 pending on viral variant, dose, and the site of inoculation and are likely more variable in natural infections105 [12]. We therefore used 21 days as a conservative estimate. The delay between detection of outbreaks106 and laboratory diagnostics was calculated from two years of data (2013-2014) from the National Service107 for Agrarian Health of Peru (SENASA), which described delays ranging from 3 to 148 days (median =108 11; mean = 15.02; N = 264 suspected outbreaks) [13]. Finally, our estimate of the timing of reactive109 control did not account for known under-reporting of VBR cases in livestock, which would further delay110 implementation of some campaigns [14]. Our simulations therefore represent the best-case scenario for111 the reactive control strategy. We expect that longer delays arising from longer incubation periods in live-112 stock or failure to report early incidences of mortality would diminish efficacy of both intervention types113 since control would be implemented after rabies has naturally gone extinct from the local bat population,114 effectively becoming proactive control (Supplementary Figure 4).115
3.5 Introductions resulting in invasion116
Fig. 4 from the main text presented results from all 5000 stochastic simulations at each level of initial117 vaccination (N=105,000 for each R0 value). Because we introduced only a single rabid bat to the model,118 many simulations, especially at lower R0 values, resulted in stochastic die off or failure to transmit rabies119 from this infected bat. Supplementary Figure 5 illustrates the outbreak size of rabies when the introduced120 bat infected at least one other bat. Increased initial vaccine application led to smaller outbreaks.121
3.6 Sensitivity analysis of increased orotopical transfer of vaccines and vampiricide122
Given our expectation that RB transfer rates are a lower bound on vampiricide or vaccine spread, we123 simulated effects of increased levels of transfer on rabies dynamics. For completeness, we also simulated124 decreased vaccine/vampiricide spread relative to RB. We explored values ranging from 75% less (.463125 other bats) than the estimated RB value (1.85 other bats) to ten times that (18.5 other bats), which126
10
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Supplementary Figure 4: Timing of application and outbreaks for preventative, proactive, and reactive modelsimulations. Application indicates the date of either vaccine or vampiricide application. Values to the left of eachtimeline (I) indicate the number of bats assumed to have protective immunity from surviving previous natural rabiesexposures
exceeds the largest reported value of vampiricide spread [15]. We simulated the percent of the colony127 that vampiricide or vaccine was initially applied to (0 to 100, at increments of 5%) and the RB transfer128 multiplier (0.25–10) for each rabies (R0) value under each of the three intervention strategies (preventative,129 proactive, and reactive), 5000 times. Supplementary Figure 6 shows the difference between vaccination130 and culling at each point. This highlights that the benefits of preventative and proactive vaccination at131 low application levels hold even if both agents are far more transmissible than assumed in our main132 models, while culling is never favored. For the reactive strategy, vaccination was slightly favored at low133 levels of application when the spread was equal to, or less than our field estimate, while culling was134 advantageous if large fractions of bats could be captured or if agents spread twice as efficiently as our135 field data suggest. Supplementary Figures 7-8 show the reduction in rabies cases due to vaccination and136 culling, respectively. In most simulations, increasing the orotopical transfer rate above 2x past 25% initial137 application resulted in minimal additional reduction in rabies cases, indicating diminishing returns. This138 is likely because at increased application or transfer levels, most of the colony had already either been139
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Supplementary Figure 5: Size of rabies outbreaks sizes after vaccination in simulations where rabies spreadfollowing introduction. Lines show mean rabies outbreak sizes after a single rabid bat is introduced to the colonyone week following immunization. Colors represent varying degrees of rabies R0, with 95% confidence intervalscalculated from all simulations that resulted in rabies transmission. Dashed lines indicate the percent of bats thatRB was applied to in each of our study sites.
protected or culled.140 Although we expected vaccines to transfer more, not less, efficiently than vampiricide (see main text),141 we also conducted an analysis where we allowed vampiricide to spread better than vaccines to identify142 how much more a transferable vampiricide would need to be to eclipse vaccination as the preferred143 disease control agent. Supplementary Figure 9 displays the averaged results of these simulations at144 each combination. At realistic application levels when rabies (R0) was 2 or the control strategy was145 reactive, increasing vampiricide transfer rates showed significant additional reductions in rabies cases146 when compared to the empirically estimated vaccine transfer rates. Under the two lower rabies (R0) values147
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for both the preventative and proactive strategies, vampiricide was never more effective than vaccines at148 reducing rabies outbreaks under realistic application levels.149
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Supplementary Figure 6: Differences between vaccination and culling in the percent reduction of rabies casescompared to a no intervention scenario. The figure shows results of simulations assuming vaccines had transferrates that were lower than (<1x), equal to (1x) or greater than (>1x) those observed in field studies with RB(1.85 transfers per treated bat) across various levels of initial application. For example, 10x indicates that bothvampiricide and vaccines spread 10 times better than RB and 0.25x implies that real interventions spread only 25%as effectively as RB. Colors indicate the difference in reduction between vaccination and culling with red favoringvaccination and blue favoring culling. Results from the main text correspond to the 1x row in this figure.
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Supplementary Figure 7: Simulated reduction in rabies outbreak sizes under various levels of initial vaccineapplication assuming vaccines had transfer rates that were lower than (<1x), equal to (1x) or greater than (>1x)those observed in field studies with RB (1.85 transfers per treated bat).
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Supplementary Figure 8: Simulated reduction in rabies outbreak sizes under various levels of initial vampiricideapplication assuming vampiricide had transfer rates that were lower than (<1x), equal to (1x), or greater than (>1x)those observed in field studies with RB (1.85 transfers per treated bat).
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Supplementary Figure 9: Simulated reduction in outbreak sizes due to vaccination (black) and culling (light yellow)at the estimated RB level and if assuming that vampiricide spreads up to 3x more effectively than a vaccine.
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